News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Product Launches To Fuel Expansion For Systemic Lupus Erythematosus And Lupus Nephritis Treatment Markets By 2022, Says Globaldata


2/27/2014 8:33:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, UK (GlobalData), 27 February 2014 - The Systemic Lupus Erythematosus (SLE) treatment market in the seven major countries (7MM) will increase significantly in value over the coming years, jumping from approximately $473.6 million in 2012 to $1.1 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 9.36%, according to a recent report by research and consulting firm GlobalData.

The company’s report* also states that the total revenues for Lupus Nephritis (LN) in the 7MM – the US, France, Germany, Italy, Spain, the UK and Japan – will climb from an estimated $216.6 million in 2012 to $505.9 million by the end of the forecast period, representing a slightly lower CAGR of 8.86%.

GlobalData attributes the anticipated growth in both markets to the higher uptake of Benlysta and off-label Rituxan, along with the introduction of new biological therapies and overall increase in prevalent cases of SLE and LN across the 7MM during the forecast period.

Toli Koutsokeras, Analyst for GlobalData, says: “The approval of Benlysta in 2011, which made it the first product to gain marketing approval for SLE patients in more than 50 years, has paved the way for the introduction of new disease-modifying treatments and reignited the interest of pharmaceutical developers in this therapy area.”

Currently, all late-stage pipeline products for lupus are biologic drugs that will compete with Benlysta and offer new treatment options to patients. These include Anthera Pharmaceuticals’ blisibimod, Eli Lilly’s tabalumab and Merck Serono’s atacicept, which are anti-BLyS therapies.

Also in the late-stage pipeline are UCB’s epratuzumab, ImmuPharma’s Lupuzor and Bristol-Myers Squibb’s Orencia, which all boast novel mechanisms of action.

Koutsokeras continues: “With a number of products still in development, the lupus therapeutics market remains characterized by significant unmet needs. LN patients are greatly underserved with currently available treatments, and the mortality of all lupus patients remains high when compared with the general population.

“As a result, the most pressing unmet need is for the development of new therapies that boast more positive safety profiles, offer potent clinical benefits to patients and expand their treatment options,” the analyst concludes.

*PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022

This report provides an overview of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the SLE and LN therapeutics markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx

-ABOUT GLOBALDATA-

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES